Clinical Study on Spectramune® Immune Defense Complex that Demonstrates Reduced Incidence of Illness and Less Severe Symptoms

Clinical Study on Spectramune®  Immune Defense Complex  that Demonstrates Reduced Incidence of Illness and Less Severe Symptoms

The clinical study  on Spectramune Immune Defense Complex is currently not published, but we would like to provide you with more information on the trial. Please fill out the form on this page and we will contact you.

Study Highlights

In a 12-week randomized, double-blind, placebo-controlled, parallel design study, 120 healthy men and women (age 30-60)  were given 250 mg or 500 mg of Spectramune or a matching placebo. The primary outcome measured was upper respiratory symptom severity via the Wisconsin Upper Respiratory Symptoms Scale (WURSS-24). Testing of subjects was done at baseline, 3, 6, and 12 weeks. A range of biomarkers was measured at baseline and 12 weeks.

Spectramune subjects experienced: 

• 23% fewer episodes of respiratory illness and 23% fewer days sick than those taking a  placebo. 
• 30% less severe symptoms, and those symptoms had a 23% reduction in impact on their daily activities compared to those taking placebo. 
• Less severe nasal, throat/cough, and systemic symptoms over 12 weeks of supplementation.
• Significantly improved psychological wellbeing within the first three weeks, greater than 2x improvement over baseline at 12 weeks regardless of dose.